Published in J Transl Med on June 09, 2008
JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol (2009) 1.32
Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunology (2014) 0.97
Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease. Transpl Infect Dis (2010) 0.91
Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis (2014) 0.87
A HCMV pp65 polypeptide promotes the expansion of CD4+ and CD8+ T cells across a wide range of HLA specificities. J Cell Mol Med (2009) 0.85
An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients. PLoS One (2012) 0.83
Diagnostic Usefulness of Cytomegalovirus (CMV)-Specific T Cell Immunity in Predicting CMV Infection after Kidney Transplantation: A Pilot Proof-of-Concept Study. Infect Chemother (2015) 0.82
Age-dependent association between low frequency of CD27/CD28 expression on pp65 CD8+ T cells and cytomegalovirus replication after transplantation. Clin Vaccine Immunol (2009) 0.82
Evaluation of virus-specific cellular immune response in transplant patients. World J Virol (2012) 0.80
Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy. J Clin Virol (2012) 0.78
An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity. BMC Immunol (2017) 0.78
The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV. Transplantation (2016) 0.76
Clinical factors influencing phenotype of HCMV-specific CD8+ T cells and HCMV-induced interferon-gamma production after allogeneic stem cells transplantation. Clin Dev Immunol (2013) 0.76
Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients. J Clin Immunol (2012) 0.76
Surveillance of γδ T Cells Predicts Cytomegalovirus Infection Resolution in Kidney Transplants. J Am Soc Nephrol (2015) 0.76
Cytomegalovirus-Responsive CD8(+) T Cells Expand After Solid Organ Transplantation in the Absence of CMV Disease. Am J Transplant (2017) 0.76
Clinical Experience with Immune Monitoring for Cytomegalovirus in Solid-Organ Transplant Recipients. Curr Infect Dis Rep (2013) 0.75
Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipients. J Transl Med (2015) 0.75
Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC Immunol (2017) 0.75
Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies. Infect Chemother (2017) 0.75
Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med (2005) 7.18
Infection in organ-transplant recipients. N Engl J Med (1998) 6.49
Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet (2000) 4.67
Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis (2002) 4.65
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet (2000) 3.22
Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood (2002) 2.83
Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med (2005) 2.28
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant (2004) 2.23
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients. Transplantation (2003) 2.05
Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat (2002) 2.00
Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol (2004) 1.89
Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis (2007) 1.88
Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis (2001) 1.77
Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant (2005) 1.73
Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation (2001) 1.54
Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant (2006) 1.52
Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation (2001) 1.50
Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis (2004) 1.35
Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis (1999) 1.35
Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis (2002) 1.28
Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant (2005) 1.26
Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant (2004) 1.14
Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol (2002) 1.14
Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation (2006) 1.11
Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis (1999) 1.09
Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis (2006) 1.09
Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis (2002) 1.08
Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant (2005) 1.06
Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Res (2002) 1.04
Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 1.01
Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J Infect Dis (2006) 0.98
Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant (2004) 0.96
Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients. Am J Transplant (2007) 0.93
Persistent cytomegalovirus infection is associated with increased expression of TGF-beta1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts. Nephrol Dial Transplant (2005) 0.91
Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int (2006) 0.87
Viral dynamics in transplant patients: implications for disease. Lancet Infect Dis (2007) 0.86
Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis (1999) 0.83
Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection. Clin Microbiol Infect (2004) 0.78
Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation (2005) 3.57
Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis (2009) 3.23
Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity (2013) 2.74
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol (2010) 2.02
Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int (2008) 1.84
The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation (2009) 1.81
Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis (2008) 1.79
T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology (2013) 1.77
Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transpl Int (2005) 1.65
Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant (2004) 1.64
Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med (2008) 1.60
Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease. Am J Respir Crit Care Med (2014) 1.58
Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation (2007) 1.56
Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transplant (2006) 1.54
Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis (2009) 1.53
Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies. Eur J Immunol (2013) 1.52
Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation (2009) 1.47
Morbidity and mortality on chronic haemodialysis: a 10-year Swiss single centre analysis. Swiss Med Wkly (2011) 1.47
Human polyomaviruses in disease and cancer. Virology (2013) 1.47
Kidney retransplantation following graft loss to polyoma virus-associated nephropathy: an effective treatment option in simultaneous pancreas and kidney transplant recipients. Transpl Int (2007) 1.44
Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. J Virol (2010) 1.41
Comparison of CT angiography with MR angiography in the preoperative assessment of living kidney donors. Transplantation (2008) 1.39
VP1 messenger RNA levels in urine for diagnosing BK virus nephropathy? Transplantation (2003) 1.38
JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol (2009) 1.32
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS (2006) 1.28
Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant (2005) 1.26
Numerical modelling of label-structured cell population growth using CFSE distribution data. Theor Biol Med Model (2007) 1.25
Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett (2005) 1.25
Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient. Am J Transplant (2005) 1.24
Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS One (2011) 1.24
Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J Virol (2002) 1.23
Transcription of the Staphylococcus aureus cid and lrg murein hydrolase regulators is affected by sigma factor B. J Bacteriol (2004) 1.23
Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. Transplantation (2009) 1.21
Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant (2010) 1.21
HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med (2007) 1.20
Cofilin peptide homologs interfere with immunological synapse formation and T cell activation. Proc Natl Acad Sci U S A (2004) 1.18
Monocyte heterogeneity in human cardiovascular disease. Immunobiology (2012) 1.15
Co-infection of Influenza B and Streptococci causing severe pneumonia and septic shock in healthy women. BMC Infect Dis (2010) 1.15
Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant (2007) 1.15
Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods. Hum Pathol (2005) 1.14
Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antivir Ther (2007) 1.14
Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol (2002) 1.14
Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS (2008) 1.13
JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis (2011) 1.13
Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int (2004) 1.11
Functional analysis of polyomavirus BK non-coding control region quasispecies from kidney transplant recipients. J Med Virol (2009) 1.11
Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti Infect Ther (2007) 1.11
Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res (2006) 1.09
Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol (2002) 1.08
Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation (2003) 1.08
Polyomavirus-associated nephropathy in renal transplantation: critical issues of screening and management. Adv Exp Med Biol (2006) 1.07
BK virus infection, replication, and diseases in pediatric kidney transplantation. Pediatr Nephrol (2007) 1.05
The specific monocarboxylate transporter (MCT1) inhibitor, AR-C117977, a novel immunosuppressant, prolongs allograft survival in the mouse. Transplantation (2007) 1.05
Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J Virol (2009) 1.04
Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation (2011) 1.03
Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int (2003) 1.03
A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine (2013) 1.01
Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant (2006) 1.00
The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant Rev (Orlando) (2011) 1.00
Costimulation induced phosphorylation of L-plastin facilitates surface transport of the T cell activation molecules CD69 and CD25. Eur J Immunol (2007) 1.00
Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS One (2008) 1.00
1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob Agents Chemother (2010) 1.00
The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J (2012) 0.99
Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int (2007) 0.98
Age-related decrease in adenovirus-specific T cell responses. J Infect Dis (2002) 0.97
Pan-dengue virus detection by PCR for travelers returning from the tropics. J Clin Microbiol (2008) 0.96
Rapid dynamics of polyomavirus type BK in renal transplant recipients. J Infect Dis (2005) 0.96
The human polyomaviruses: from orphans and mutants to patchwork family. APMIS (2013) 0.96
Diagnosis and treatment of latent infection with Mycobacterium tuberculosis. Respirology (2013) 0.96
Cellular immune responses to BK virus. Curr Opin Organ Transplant (2008) 0.96
Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study. AIDS (2010) 0.96
Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors. J Transl Med (2006) 0.95
The fraction of perforin-expressing HIV-specific CD8 T cells is a marker for disease progression in HIV infection. AIDS (2002) 0.95
The polyomavirus BK agnoprotein co-localizes with lipid droplets. Virology (2010) 0.95
Antiretroviral therapy after cryptococcal meningitis. N Engl J Med (2014) 0.95
Human polyomavirus type 1 (BK virus) agnoprotein is abundantly expressed but immunologically ignored. Clin Vaccine Immunol (2007) 0.94
ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies. Nephrol Dial Transplant (2008) 0.94
Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int (2002) 0.94
Detection of HLA-antibodies prior to renal transplantation: prospects and limitations of new assays. Swiss Med Wkly (2008) 0.94
Acute renal failure on immune reconstitution in an HIV-positive patient with miliary tuberculosis. Clin Infect Dis (2004) 0.93
Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies. Transplantation (2008) 0.93
Differential kinetics of effector and regulatory T cells in patients on calcineurin inhibitor-based drug regimens. Kidney Int (2009) 0.93
Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol (2003) 0.93
Contribution of early failure to outcome on peritoneal dialysis. Perit Dial Int (2008) 0.92